Newsroom

AI-based heart failure phenotyping enables high-validity evidence

Publications

Researchers from Amgen, Harvard, Providence, and Verantos published a paper in BMJ Open comparing the use of various types of data and technology in understanding heart failure subgroups and associated signs, symptoms, and comorbidities. Accuracy was 45% greater using Verantos AI than traditional approaches. This groundbreaking work highlights Verantos’ market-leading technology and how better treatment decisions can be made using granular heart failure subgroups extracted from routinely collected data.

Read at the original outlet
All news
Get started

Ready to advance your evidence program?

Speak with our team about how the Verantos pharmacoepidemiology stack can accelerate your timeline.